Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-08-17 Regulatory Filings
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains an announcement about the purchase of common shares by the Executive Chairman, referenced as Exhibit 99.1. The document is short (2792 characters) and primarily serves to furnish this announcement rather than provide detailed financial data or a full report. It does not contain financial statements or substantive financial analysis. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a certification or officer attestation. Given the nature of the filing and its content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-08-17 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It contains an announcement about a news service release regarding a presentation at a conference. The document is relatively short (2933 characters) and primarily serves to furnish an announcement rather than provide detailed financial data or a full report. It explicitly states that the attached exhibit is a news service announcement and is not "filed" for certain regulatory purposes. This aligns with the characteristics of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain substantive financial statements or detailed report content. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-08-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Tiziana Life Sciences LTD, pursuant to SEC rules. It announces the appointment of a new Chief Medical Officer and Acting Chief Scientific Officer. The document is short (2845 characters) and primarily serves as an announcement of a management change rather than a full report. It does not contain financial statements or detailed management discussion. The key content is the appointment of a senior executive, which fits the category of Board/Management Information (MANG).
2022-07-18 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 6-K, which is a current report filed by foreign private issuers to disclose material information. The content specifically announces the resignation of the CEO and appointment of an interim CEO, along with a press release. There are no financial statements or detailed financial data present. The document is short (2860 characters) and primarily serves as a regulatory announcement of management changes. Therefore, it fits best under Board/Management Information (MANG).
2022-07-15 English
ANNUAL REPORT
Annual Report FY 2021
2022-05-21 English
SCHEDULE 13G
Major Shareholding Notification
2022-05-04 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.